In this article, we will discuss Ramucirumab (18). So, let’s get started.
Clinical Deterioration in Patients with Child-Pugh B or C Cirrhosis: Clinical deterioration, manifested by new onset or worsening encephalopathy, ascites, or hepatorenal syndrome was reported in patients with Child-Pugh B or C cirrhosis who received single-agent Ramucirumab. Use Ramucirumab in patients with Child-Pugh B or C cirrhosis only if the potential benefits of treatment are
judged to outweigh the risks of clinical deterioration.